Vectura Group PLC (LON:VEC) has been assigned an average recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is GBX 169.14 ($2.34).
VEC has been the topic of a number of research reports. Panmure Gordon reiterated a “buy” rating and set a GBX 150 ($2.07) price target on shares of Vectura Group in a research report on Thursday, November 9th. Numis Securities dropped their price target on Vectura Group from GBX 205 ($2.83) to GBX 170 ($2.35) and set a “buy” rating on the stock in a research report on Thursday, November 9th. Shore Capital reiterated a “buy” rating on shares of Vectura Group in a research report on Thursday, November 9th. Finally, Peel Hunt reiterated a “hold” rating and set a GBX 160 ($2.21) price target on shares of Vectura Group in a research report on Thursday, January 4th.
Shares of Vectura Group (LON VEC) traded up GBX 1.35 ($0.02) during trading on Tuesday, hitting GBX 79.05 ($1.09). The stock had a trading volume of 3,611,196 shares, compared to its average volume of 5,050,000. Vectura Group has a fifty-two week low of GBX 70.50 ($0.97) and a fifty-two week high of GBX 166.97 ($2.31).
About Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.